Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enzon Pharmaceuticals has announced that Oncaspar-IV, its next generation pegylated L-asparaginase, received approval from the Commission of the European Communities for designation as an orphan medicinal product.
Subscribe to our email newsletter
Enzon is developing Oncaspar-IV to enhance the pharmaceutical properties of the currently available product. Oncaspar-IV utilizes an efficient modern process for manufacturing of L-asparaginase, and an improved PEG linker to enhance stability, said Enzon.
Jeffrey Buchalter, chairman and CEO of Enzon, said: “Today’s announcement is a significant milestone in our overall plan to market the new Oncaspar-IV in new geographic territories. We are currently developing the next-generation Oncaspar product to enhance the pharmaceutical properties of the approved version currently marketed in the US.”